Methadone Peak and Trough Levels: What the Ratio Actually Tells You
Two people can take exactly the same methadone dose and have completely different experiences. One is stable for twenty-four hours. The other is fine in the afternoon and in withdrawal by early morning, and is often told they must be using on the side.
Frequently they are not. They are metabolising the drug faster, and a blood level test can show it. That is what peak and trough levels are for.
What peak and trough actually mean
Peak is the highest concentration of methadone in the blood after a dose. Trough is the lowest, immediately before the next one. Together they describe not just how much drug is present, but how quickly it is disappearing.
The standard timing:
- Peak — drawn about 3 to 4 hours after the morning dose
- Trough — drawn just before the next morning dose, at the end of the interval
Timing matters more than most people realise. A “peak” taken six hours after dosing is not a peak, and it will make a fast metaboliser look normal.
What the numbers mean — and what they do not
A range of roughly 200 to 600 ng/mL has long been used as a clinical guide, with peak levels generally expected above 400 ng/mL.
But there is no true therapeutic window for methadone. Response varies so widely between individuals that a single number cannot tell you whether a dose is right. Some people are comfortable and stable below the “guide” range; others are in withdrawal inside it.
Levels are a tool for explaining a problem, not a target to be dosed toward. How the patient actually feels across the twenty-four hours remains the primary evidence.
The ratio is the useful number
The single figure that carries the most clinical information is not the peak or the trough on its own. It is the ratio between them.
A peak-to-trough ratio greater than 2 indicates faster clearance than the usual 24-hour norm. In other words, the drug is being cleared quickly enough that a once-daily dose cannot hold a steady level across the whole day.
This is what documents rapid metabolism, and it is the objective evidence that separates “this person is metabolising fast” from “this person is not taking their dose as directed.”
This distinction has real consequences. Someone in daily inter-dose withdrawal who is assumed to be diverting or using is treated as a behaviour problem. The same person with a documented ratio above 2 has a pharmacokinetic problem, and pharmacokinetic problems have solutions.
Split dosing
The usual response to a high peak-to-trough ratio is split dosing — the same total daily amount divided into two administrations rather than one. That flattens the curve: lower peak, higher trough, less swing across the day.
It is not a dose increase, which is a distinction worth being clear about, because simply raising a once-daily dose in a rapid metaboliser tends to push the peak higher without meaningfully lifting the trough — more sedation after dosing, still in withdrawal before the next one.
Split dosing does carry practical and regulatory friction around take-home medication, which is part of why documenting the ratio matters. It is the evidence that supports the request.
The metabolism fact most sources still get wrong
If you look up why methadone levels vary, you will very often be told that methadone is metabolised primarily by the liver enzyme CYP3A4. That was the long-standing assumption, and it is still repeated widely in patient-facing material.
The pharmacology literature has since established that CYP2B6, not CYP3A4, is the principal determinant of methadone metabolism, clearance, elimination and plasma concentration in humans.
This is not a technicality. It changes which genetic variation matters and which drug interactions are the ones to watch. CYP2B6 varies genetically between individuals, which is a large part of why two people on identical doses clear the drug at different rates — and why rapid metabolism is a real physiological phenomenon rather than a suspicion about compliance.
Methadone remains highly susceptible to both inducing and inhibiting drug interactions. Any new medication — prescribed, over-the-counter, or herbal — is worth raising with the clinic, because a substantial shift in clearance can present either as withdrawal or as oversedation.
If you also use methamphetamine or another stimulant
This is the part rarely covered anywhere, and it matters, because stimulant use among people in opioid treatment is common — and rising as the opioid and stimulant supplies have converged.
Methadone prolongs the QT interval. It does so by inhibiting a cardiac potassium channel encoded by the hERG gene, and it is well recognised as a cause of QT prolongation and, rarely, torsades de pointes — a dangerous ventricular arrhythmia.
Methamphetamine also prolongs the QT interval. Stimulant-induced QT prolongation is documented, including reported cases of methamphetamine-induced torsades.
Used together, those effects are additive. Someone on methadone maintenance who is also using meth is stacking two QT-prolonging exposures on the same heart, and the risk rises with methadone dose and blood concentration — which is precisely what peak levels measure.
Low potassium (hypokalemia) is a recognised contributing factor, and it is common in people who are dehydrated, not eating, or bingeing — the physiological state that follows a stimulant binge.
What to do with that. Tell the clinic. This is genuinely one of the situations where concealing stimulant use is more dangerous than disclosing it, because the clinical response is not punishment — it is an ECG. Knowing your QTc changes how methadone is dosed and monitored, and it is a simple, quick, non-invasive test.
Seek urgent care for fainting, near-fainting, palpitations, or a racing irregular heartbeat while on methadone. Those are not symptoms to explain away.
Questions worth asking your clinic
- If I am in withdrawal before my next dose, can we check a peak and trough?
- What was the ratio, and does it suggest rapid metabolism?
- If it does, is split dosing an option here, and what would that involve for take-homes?
- Have I had an ECG, and what is my QTc?
- Do any of my other medications interact with methadone metabolism?
These are ordinary, reasonable questions. A programme that treats them as a challenge rather than a clinical conversation is worth noticing.
Help: SAMHSA National Helpline — 1-800-662-4357, free and confidential, 24/7. Emergency: 911. Mental health crisis: 988.
Meth treatment and recovery · Contingency management — the best-evidenced stimulant treatment, and it works alongside opioid medication rather than competing with it
Sources
- Kharasch ED. Current concepts in methadone metabolism and transport. Clinical Pharmacology in Drug Development. 2017.
- Chapter 3B: Methadone — Medications for Opioid Use Disorder. SAMHSA TIP 63, NCBI Bookshelf.
- QTc prolongation and torsades de pointes in individuals undergoing methadone maintenance treatment: a systematic review and meta-analysis. PubMed Central.
- A case of methamphetamine-induced torsades de pointes. CHEST.
- Divided doses for methadone maintenance. American Journal of Psychiatry.
General information, not medical advice — and not a substitute for care from a qualified clinician. This page has not been reviewed by a licensed clinician (medical review policy).
Need help now? SAMHSA 1-800-662-4357 — free, 24/7. In an emergency, call 911. Published by PopNet Media LLC. Editorial policy · Sources · Corrections · Advertising disclosure.
